

## Supplementary Online Content


Holland EJ, Jackson MA, Donnenfeld E, et al. Efficacy of lifitegrast ophthalmic solution, 5.0%, in patients with moderate to severe dry eye disease: a post hoc analysis of 2 randomized clinical trials. *JAMA Ophthalmol*. Published online October 7, 2021. doi:10.1001/jamaophthalmol.2021.3943

**eFigure 1.** Percentage of Participants With DED and Improvement in Symptoms (EDS) From Baseline to Day 84, by Treatment Group (Pooled Data)

**eFigure 2.** Percentage of Participants With DED and Improvement in Symptoms (Global VAS) From Baseline to Day 84, by Treatment Group (Pooled Data)

This supplementary material has been provided by the authors to give readers additional information about their work.

**eFigure 1. Percentage of Participants With DED and Improvement in Symptoms (EDS) From Baseline to Day 84, by Treatment Group (Pooled Data)**




Eye Dryness Score (VAS) using 0 - 100 point scale (0 = no discomfort, 100 = maximal discomfort).

The bars are the exact 95% CI of percents.

ITT population with LOCF

CI, confidence interval; EDS, eye dryness score; ITT, intent-to-treat; LOCF, last observation carried forward; LIF, lifitegrast; VAS, visual analog scale

**eFigure 2. Percentage of Participants With DED and Improvement in Symptoms (Global VAS) From Baseline to Day 84, by Treatment Group (Pooled Data)**



Eye Dryness Score (VAS) using 0 - 100 point scale (0 = no discomfort, 100 = maximal discomfort).

The bars are the exact 95% CI of percents.

ITT population with LOCF

CI, confidence interval; EDS, eye dryness score; ITT, intent-to-treat; LOCF, last observation carried forward; LIF, lifitegrast; VAS, visual analog scale